105 related articles for article (PubMed ID: 17623737)
1. Failure of allogeneic bone marrow transplantation to arrest disease activity in multiple sclerosis.
Jeffery DR
Mult Scler; 2007 Sep; 13(8):1071-5. PubMed ID: 17623737
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis.
McAllister LD; Beatty PG; Rose J
Bone Marrow Transplant; 1997 Feb; 19(4):395-7. PubMed ID: 9051253
[TBL] [Abstract][Full Text] [Related]
3. Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: perspective on mechanisms of action.
Van Wijmeersch B; Sprangers B; Dubois B; Waer M; Billiau AD
J Neuroimmunol; 2008 Jul; 197(2):89-98. PubMed ID: 18541311
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Karussis D; Slavin S
J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect.
Van Wijmeersch B; Sprangers B; Rutgeerts O; Lenaerts C; Landuyt W; Waer M; Billiau AD; Dubois B
Biol Blood Marrow Transplant; 2007 Jun; 13(6):627-37. PubMed ID: 17531772
[TBL] [Abstract][Full Text] [Related]
6. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation.
Lu JQ; Storek J; Metz L; Yong VW; Stevens AM; Nash RA; Joseph JT
Arch Neurol; 2009 Jan; 66(1):116-20. PubMed ID: 19139309
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.
Metz I; Lucchinetti CF; Openshaw H; Garcia-Merino A; Lassmann H; Freedman MS; Atkins HL; Azzarelli B; Kolar OJ; Brück W
Brain; 2007 May; 130(Pt 5):1254-62. PubMed ID: 17293360
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis preceding CNS lymphoma: a case report.
Yang JH; Wu SL
Acta Neurol Taiwan; 2007 Jun; 16(2):92-7. PubMed ID: 17685133
[TBL] [Abstract][Full Text] [Related]
9. [Autologous bone marrow transplantation as a treatment for autoimmune disease: mechanisms and results].
Garza-Madrid ME; Borbolla-Escoboza JR; López-Hernández MA
Gac Med Mex; 2004; 140(5):531-9. PubMed ID: 15559235
[TBL] [Abstract][Full Text] [Related]
10. Homogeneity of active demyelinating lesions in established multiple sclerosis.
Breij EC; Brink BP; Veerhuis R; van den Berg C; Vloet R; Yan R; Dijkstra CD; van der Valk P; Bö L
Ann Neurol; 2008 Jan; 63(1):16-25. PubMed ID: 18232012
[TBL] [Abstract][Full Text] [Related]
11. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
12. [The molecular characteristics of T-cell immune reconstitution in leukemia patients after allogeneic hematopoietic stem cell transplantation].
Fu YW; Wu DP; Sun AN; Feng YF; Chang WR; Zhu ZL; Zhu P
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):312-7. PubMed ID: 17877159
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation: does it stop MS progression?
Freedman MS
J Neurol Sci; 2007 Aug; 259(1-2):85-9. PubMed ID: 17560611
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome.
Kimiskidis V; Sakellari I; Tsimourtou V; Kapina V; Papagiannopoulos S; Kazis D; Vlaikidis N; Anagnostopoulos A; Fassas A
Mult Scler; 2008 Mar; 14(2):278-83. PubMed ID: 17942513
[TBL] [Abstract][Full Text] [Related]
15. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
[TBL] [Abstract][Full Text] [Related]
16. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
Holmøy T
Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322
[TBL] [Abstract][Full Text] [Related]
17. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
Huang YH; Zozulya AL; Weidenfeller C; Metz I; Buck D; Toyka KV; Brück W; Wiendl H
Ann Neurol; 2009 Aug; 66(2):171-83. PubMed ID: 19705413
[TBL] [Abstract][Full Text] [Related]
18. DNA-based vaccines: the future of multiple sclerosis therapy?
Stüve O; Cravens PD; Eagar TN
Expert Rev Neurother; 2008 Mar; 8(3):351-60. PubMed ID: 18345967
[TBL] [Abstract][Full Text] [Related]
19. Immunopathogenesis of multiple sclerosis.
Agrawal SM; Yong VW
Int Rev Neurobiol; 2007; 79():99-126. PubMed ID: 17531839
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab treatment in pediatric multiple sclerosis: a case report.
Borriello G; Prosperini L; Luchetti A; Pozzilli C
Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
